Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry.
81 patients with advanced prostate carcinoma, mainly estrogen resistant, were treated with Estracyt. After a pilot study had shown encouraging results in the first 39 cases, the preparation was used on a further 42 patients and for 38 of these its therapeutic effectiveness was evaluated according to internationally defined clinical criteria. In this way, an objective therapeutic success quota of 55% of all 38 patients was obtained. In the group with estrogen-resistant tumors the value was still found to be as high as 35%. These clinical results were confirmed by cytomorphological control of the degree of regression of the tumor effected by the therapy, and also by single-cell cytophotometric analysis of the DNA content of various prostate carcinomas treated wtih Estracyt.
D001707:Biopsy, Needle; D004273:DNA, Neoplasm / Q000032:analysis; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010783:Photometry; D011471:Prostatic Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology
D004273:DNA, Neoplasm; D009588:Nitrogen Mustard Compounds; D004961:Estramustine